Combretastatin A4 phosphate.Citation formats

Standard

Combretastatin A4 phosphate. / West, CML; Price, PM.

In: Anticancer Drugs, Vol. 15( 3), 03.2004, p. 179-87.

Research output: Contribution to journalArticlepeer-review

Harvard

West, CML & Price, PM 2004, 'Combretastatin A4 phosphate.', Anticancer Drugs, vol. 15( 3), pp. 179-87.

APA

West, CML., & Price, PM. (2004). Combretastatin A4 phosphate. Anticancer Drugs, 15( 3), 179-87.

Vancouver

West CML, Price PM. Combretastatin A4 phosphate. Anticancer Drugs. 2004 Mar;15( 3):179-87.

Author

West, CML ; Price, PM. / Combretastatin A4 phosphate. In: Anticancer Drugs. 2004 ; Vol. 15( 3). pp. 179-87.

Bibtex

@article{d873607af5dc4eb9a4897d40c9c3a0f8,
title = "Combretastatin A4 phosphate.",
abstract = "Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial cells. These changes increase vascular permeability and disrupt tumor blood flow. In experimental tumors, anti-vascular effects are seen within minutes of drug administration and rapidly lead to extensive ischemic necrosis in areas that are often resistant to conventional anti-cancer treatments. Following single-dose administration a viable tumor rim typically remains from which tumor regrowth occurs. When given in combination with therapies targeted at the proliferating viable rim, enhanced tumor responses are seen and in some cases cures. Results from the first clinical trials have shown that CA4P monotherapy is safe and reduces tumor blood flow. There has been some promising demonstration of efficacy. CA4P in combination with cisplatin is also safe. Functional imaging studies have been used to aid the selection of doses for phase II trials. Both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography can measure the anti-vascular effects of CA4P in humans. This review describes the background to the development of CA4P, its proposed mechanism of action, the results from the first clinical trials with CA4P and the role of imaging techniques in its clinical development.",
keywords = "Animals, pharmacology: Antineoplastic Agents, Phytogenic, statistics & numerical data: Clinical Trials, Humans, drug therapy: Neoplasms, drug therapy: Neovascularization, Pathologic, Research Support, Non-U.S. Gov't, pharmacology: Stilbenes, methods: Technology, Pharmaceutical",
author = "CML West and PM. Price",
year = "2004",
month = mar,
language = "English",
volume = "15( 3)",
pages = "179--87",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams & Wilkins",

}

RIS

TY - JOUR

T1 - Combretastatin A4 phosphate.

AU - West, CML

AU - Price, PM.

PY - 2004/3

Y1 - 2004/3

N2 - Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial cells. These changes increase vascular permeability and disrupt tumor blood flow. In experimental tumors, anti-vascular effects are seen within minutes of drug administration and rapidly lead to extensive ischemic necrosis in areas that are often resistant to conventional anti-cancer treatments. Following single-dose administration a viable tumor rim typically remains from which tumor regrowth occurs. When given in combination with therapies targeted at the proliferating viable rim, enhanced tumor responses are seen and in some cases cures. Results from the first clinical trials have shown that CA4P monotherapy is safe and reduces tumor blood flow. There has been some promising demonstration of efficacy. CA4P in combination with cisplatin is also safe. Functional imaging studies have been used to aid the selection of doses for phase II trials. Both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography can measure the anti-vascular effects of CA4P in humans. This review describes the background to the development of CA4P, its proposed mechanism of action, the results from the first clinical trials with CA4P and the role of imaging techniques in its clinical development.

AB - Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial cells. These changes increase vascular permeability and disrupt tumor blood flow. In experimental tumors, anti-vascular effects are seen within minutes of drug administration and rapidly lead to extensive ischemic necrosis in areas that are often resistant to conventional anti-cancer treatments. Following single-dose administration a viable tumor rim typically remains from which tumor regrowth occurs. When given in combination with therapies targeted at the proliferating viable rim, enhanced tumor responses are seen and in some cases cures. Results from the first clinical trials have shown that CA4P monotherapy is safe and reduces tumor blood flow. There has been some promising demonstration of efficacy. CA4P in combination with cisplatin is also safe. Functional imaging studies have been used to aid the selection of doses for phase II trials. Both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography can measure the anti-vascular effects of CA4P in humans. This review describes the background to the development of CA4P, its proposed mechanism of action, the results from the first clinical trials with CA4P and the role of imaging techniques in its clinical development.

KW - Animals

KW - pharmacology: Antineoplastic Agents, Phytogenic

KW - statistics & numerical data: Clinical Trials

KW - Humans

KW - drug therapy: Neoplasms

KW - drug therapy: Neovascularization, Pathologic

KW - Research Support, Non-U.S. Gov't

KW - pharmacology: Stilbenes

KW - methods: Technology, Pharmaceutical

M3 - Article

VL - 15( 3)

SP - 179

EP - 187

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

ER -